A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 197
- Registration Number
- NCT06681870
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT06544642
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Daytona Beach, Florida, United States
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 342
- Registration Number
- NCT06500741
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT06440967
- Locations
- 🇨🇦
Site CA15002, Montreal, Quebec, Canada
🇨🇦Site CA15001, Quebec City, Quebec, Canada
🇨🇦Site CA15003, Sherbrooke, Quebec, Canada
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06396091
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06248086
- Locations
- 🇦🇺
Site AU61008, Camperdown, New South Wales, Australia
🇦🇺Site AU61004, Fitzroy, Victoria, Australia
🇦🇺Site AU61005, Melbourne, Victoria, Australia
A Study of ASP1012 in Adults With Solid Tumors
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT06171178
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Conditions
- Interventions
- Drug: FezolinetantDrug: ParoxetineDrug: GabapentinDrug: CitalopramDrug: ClonidineDrug: PregabalinDrug: EscitalopramDrug: DesvenlafaxineDrug: OxybutyninDrug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category aboveDrug: VenlafaxineDrug: Any other SSRI/SNRI not already specified
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06049797
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Downstate Health Sciences University, Brooklyn, New York, United States
🇺🇸Mohawk Valley Health System - Womens Health Center, Utica, New York, United States
Early Access Program for Zolbetuximab
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT06048081
- Locations
- 🇺🇸
Site US10001, Morristown, New Jersey, United States
🇩🇪DE49020, Berlin, Germany
🇩🇪DE49021, Chemnitz, Germany
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT05999747
- Locations
- 🇺🇸
University of Nevada, Las Vegas, Las Vegas, Nevada, United States
🇺🇸Washington University Center, Saint Louis, Missouri, United States